## **Round Table 2:** Exploitation **Al&Genomics** *"Exploring potential applications, data integration, and partnership with the industry SMEs"*

Moderator: Prof. Fabio Massimo Zanzotto, University of Rome Tor Vergata, REVERT AI Responsible





#### **REVERT** - taRgeted thErapy for adVanced colorEctal canceR paTients



### Personalized Predictive Medicine









## Challenges







## **Explaining AI decisions to clinicians**







## Challenges Explaining AI decisions to clinicians More important challenge: evaluating XAI models







### Evaluating explainable Artificial Intelligence

#### An evaluation procedure of explainability based on Forward-simulatability (FS) for post-hoc evaluation

Method:

- Clinicians are asked to take decisions by looking at explanations
- The explanation method is good if clinicians take the same decision of the **ML** system

FS has been proposed in NLP and we overcome the limits for its application in cancer treatments

- We defined FS Score
- FSS allows comparison among different **Explanation Method**



#### **Forward-simulatability**



Scarpato, N., Nourbakhsh, A., Ferroni, Riondino, S., Roselli, M., Fallucchi, F., Barbanti, P., Guadagni, F. & Zanzotto, F.M. Evaluating Explainable Machine Learning Models for Clinicians. Cogn Comput 16, 1436–1446 (2024). https://doi.org/10.1007/s12559-024-10297-x







## Challenges Explaining AI decisions to clinicians More important challenge: evaluating XAI models







**Explaining AI decisions to clinicians** 

## Al needs training data!





## Al needs training data!

## **Exploiting retrospective patients**

Clinical data	Genomic deta	Trascriptomic data	Treatment	Follow Up	Outcome

Noemi Scarpato, Silvia Riondino, Aria Nourbakhsh, Mario Roselli, Patrizia Ferroni, Fiorella Guadagni, Fabio Massimo Zanzotto, Drug recommendation ranking for personalized medicine using outcomes of retrospective cancer patients, Expert Systems with Applications, Volume 256, 2024,





## Al needs training data!

#### **Exploiting retrospective patients**

### **Treatments change over time**

Clinical data	Genomic deta	Trascriptomic data	Treatment	Follow Up	Outcome

Noemi Scarpato, Silvia Riondino, Aria Nourbakhsh, Mario Roselli, Patrizia Ferroni, Fiorella Guadagni, Fabio Massimo Zanzotto, Drug recommendation ranking for personalized medicine using outcomes of retrospective cancer patients, Expert Systems with Applications, Volume 256, 2024,





## Al needs training data!

**Exploiting retrospective patients** 

## Treatments change over time Informed Consents are project specific

Clinical data	Genomic deta	Trascriptomic data	Treatment	Follow Up	Outcome	
				_		
	enc	Πάμι	гаі	nin	<b>P D A I</b>	2
		<b></b>			6	

Noemi Scarpato, Silvia Riondino, Aria Nourbakhsh, Mario Roselli, Patrizia Ferroni, Fiorella Guadagni, Fabio Massimo Zanzotto, Drug recommendation ranking for personalized medicine using outcomes of retrospective cancer patients, Expert Systems with Applications, Volume 256, 2024,











# GDPR Al Act







#### **REVERT** - taRgeted thErapy for adVanced colorEctal canceR paTients



# GDPR



# AI Act





## Panelists

- Alina Capitanu
- **Bjorn Rotter**
- Pablo Conesa-Zamora
- Knut Rurack
- Raniero Romagnoli Enrico Lorenzini

IMAGO, IMAGO-MOL Cluster, REVERT Partner \*

Gen XPro GMBH, REVERT Partner

ServicioMurciano de Salud, REVERT Partner

BAM, BUNDESANSTALT Bundesanstalt für Materialforschung undprüfung, REVERT Partner

Almawave Chief Technology Officer, OBDA Systems Chief Executive

Marketing Communications & Business Development Director, Alveo





### Question to Pablo

# Which to you think would be the approach for using omics data in predicting response in mCRC?





## Question to Knut

## To which extent data standardization need to be implemented at a European level to foster research in AI and Genomics?





## Question to Alina

How does the imago-Mol Cluster via MEDIC NEST Meta Cluster ensure that its industry partnerships drive innovation while remaining committed to its mission of delivering impactful, patient-centered healthcare solutions?





Question to Raniero

# Which possibilities do you see for potential application of AI in Medicine and how can this technology be accepted?





Question to Enrico

## What do you think Europe can do to foster the application of research on AI for Genomics?





## Question to Bjorn

# What are the difficulties of reaching the market with AI solutions applied to omics?





#### **REVERT** - taRgeted thErapy for adVanced colorEctal canceR paTients









# NOT enough training data! Solution Active Informed Consents

Marco Gerardi, Katarzyna Barud, Marie-Catherine Wagner, Nikolaus Forgo, Francesca Fallucchi, Noemi Scarpato, Fiorella Guadagni, Fabio Massimo Zanzotto, Active Informed Consent to Boost the Application of Machine Learning in Medicine, under review and https://arxiv.org/abs/2210.08987





## Active Informed Consents is part of a bigger project

*Key Principles* 

• Any Al system exploits human Knoxleolge

Hence

any decision of an AI system generating revenues

has to **jepay** 

the legitimate owners of this knowledge



